A therosclerosis is an inflammatory disease 1 in which a cascade of events involving C-reactive protein (CRP) deposition, complement activation, selective accumulation of monocytes and T-lymphocytes, activation of endothelial cells, and expression of chemokines and cytokines is elicited locally by tissue-deposited, modified lipoproteins. 2 Mainstream researchers regard oxidation to be the central process that transforms LDL into an atherogenic molecule. We are advancing an alternative concept, 3 however, that has evolved from the need to account for a number of findings that have not been consistent with the oxidation paradigm. We propose that LDL stranded in the connective matrix of the intima is subject to enzymatic, nonoxidative degradation by ubiquitous proteases and cholesterol esterase. Enzymatically altered LDL (E-LDL) is atherogenic because it binds CRP, thus activating complement, 4, 5 and because it provokes macrophage foam cell formation 4 and liberation of monocyte chemotactic protein-1 (MCP-1) and interleukin (IL)-6. 6 At high concentrations, E-LDL elicits cytotoxic effects on macrophages that may be due to apoptosis. 6 Further, E-LDL induces upregulation of adhesion molecules on endothelial cells and promotes the selective transmigration of monocytes and T cells to the lesion. 7 With the use of specific monoclonal antibodies, E-LDL has been shown to be present in all early human lesions. 8 E-LDL colocalized extracellularly with CRP and with terminal complement complexes. 5, 8, 9 Importantly, lipoprotein derivatives that were isolated from early atherosclerotic lesions indeed exhibited ultrastructural and biochemical features in common with E-LDL 10 -12 and had the capacity to activate complement. 10 Because E-LDL is now emerging as a novel candidate to assume the role of the prime atherogenic species, we proceeded to investigate whether its atherogenic effects may extend to smooth muscle cells (SMC). We show that E-LDL indeed alters SMC homeostasis and identify a novel pathway that could be responsible for SMC proliferation. Thus, E-LDL can produce classic changes in SMC function that are characteristic of the developing atherosclerotic lesion.
Methods

Preparation and Culture of Human Vascular SMC
Human vascular SMC were cultured from pieces of human aortas obtained during aneurysm surgery (15 donors, mean age 72 years, 10 men and 5 women) by outgrowth from explanted media fragments. 13 More than 90% of the cells were positive for ␣-actin (clone 1A4, Sigma) and showed the typical "hill-and-valley" morphology. As a negative control, cells cultivated in DMEM supplemented with the enzyme mix used for the preparation of E-LDL were used. All experiments were performed after Ͻ5 passages of culture.
Lipoprotein Isolation and Modifications
Native human LDL was isolated, 6 and enzymatic modification with trypsin, cholesterol esterase, and neuraminidase was undertaken as described. 4 The ensuing E-LDL preparations comprised a population of fused LDL particles with diameters of 25 to 500 nm. The apolipoprotein B was extensively degraded, and the ratio of free to esterified cholesterol was Ϸ1:1. The concentration of free fatty acids was not determined. Phospholipids remained quantitatively associated with the E-LDL particles. For acetylation, the standard protocol of Goldstein et al 14 was used. Lipid peroxidation was excluded by the absence of TBARS. 15 Lipoproteins were stored at 4°C and used within 1 to 2 weeks.
Staining of Foam Cells
SMC were fixed in 10% formaldehyde for 30 minutes at room temperature and intracellular lipids were stained with a saturated solution of oil-red-O for 6 hours.
Quantification of Cholesterol Uptake
Cellular cholesterol uptake was measured by the classic method described by Goldstein et al. 16 Cells were incubated with lipoproteins in the presence of [ 3 H]oleic acid (500 nmol/L; specific activity 1.8 to 2.2ϫ10 7 cpm/mL) for 12 hours at 37°C. Chromatography of the extracted lipids was performed on silica gel-TLC plates (Machery & Nagel), and radioactivity was detected in a ␤-counter (LKB-␤, Beckman Instruments). The oleic acid standard (Sigma) was used for calibration.
Reverse Transcription-Polymerase Chain Reaction of Chemokine and Cytokine mRNA RNA was isolated from confluent SMC cultures by guanidine isothiocyanate-phenol-chloroform extraction as described by Chomczynski and Sacchi. 17 Reverse transcription and reverse transcription-polymerase chain reaction was conducted as described. 6, 13 Samples lacking cDNA or RNA served as negative controls. Polymerase chain reaction products were run on 1% agarose gels in 1ϫTBE and stained with ethidium bromide. Amplification of a defined IL-6R sequence by the primers selected was ascertained by a positive signal with HepG2 cells.
Quantification of Chemokines and Cytokines
Chemokines and cytokines were determined by commercial immunoassay (IL-6, MCP-1, RANTES, MIP-1␣, and MIP-1␤, R&D Biosystems; IL-8, Innogenetics).
Chemotaxis Assay
Monocyte chemotaxis assays were performed as described previously. 6 Supernatants of E-LDL-treated SMC were assayed in dilutions from 1:1 up to 1:500. As controls, cell-free medium or supernatant dilutions containing a neutralizing monoclonal anti-MCP-1 antibody (1:200) were used (clone 24822.111, IgG1; R&D Biosystems). The chemotactic index was calculated as described previously. 6 
Immunocytochemical Detection of Surface gp130 Expression
Surface expression of gp130 was analyzed on confluent SMC cultures with a PE-labeled anti-gp130 overnight at 4°C (clone AM64, IgG1; PharMingen), as described. 13 Cells grown in the absence of lipoproteins served as controls.
Proliferation of SMC
SMC proliferation was assayed by [
3 H]thymidine incorporation into trichloroacetic acid (TCA; 5% wt/vol) precipitable material, as described. 13 Cells (2ϫ10 4 /mL) were seeded in 24-well culture plates, grown for 24 hours in complete medium, and kept in medium without additives for further 24 hours. After stimulation, cultures were pulsed with [ 3 H]thymidine (Amersham, 2 to 10 Ci/mL) for the final 6 hours of incubation, and TCA-precipitable radioactivity was quantified in a scintillation counter (LKB-␤; Beckman). SMC cultures grown in the presence of 10% human AB-serum served as positive controls. SMC grown in medium alone or in medium containing the enzyme mix used for the preparation of E-LDL served as unstimulated controls.
Detection of Cellular Toxicity and Apoptosis
Cytotoxic effects of E-LDL on SMC were determined by quantification of the reduction of intracellular ATP. 6 Apoptosis was detected by analysis of DNA fragmentations and by the TUNEL labeling technique, as described. 6 
Statistical Analysis
The significance of differences between control values and the stimulants was determined by the Mann-Whitney U test. Differences were considered significant at a level of PϽ0.05. The results are expressed as meanϮSD. Analysis was performed with SPSS software.
Results
Foam Cell Transformation of SMC Induced by E-LDL
After incubation of human SMC with 50 g/mL E-LDL for 6 hours, lipid staining with oil-red-O became positive. Native LDL did not invoke detectable foam cell transformation (Figure 1) .
Measurement of cholesterol-oleate confirmed cellular accumulation of the sterol. Accumulation of cholesterol-oleate commenced after 1 hour of incubation with E-LDL, was maximal after 12 hours, and did not increase thereafter. Native LDL was not amassed (Figure 2 ).
Selective Induction of MCP-1 mRNA Expression by E-LDL in SMC
E-LDL stimulated a pronounced, time-dependent expression of MCP-1 mRNA in SMC that was expressed after 4 hours, peaked between 12 and 48 hours, and disappeared after 72 hours ( Figure 3 ). MCP-1 mRNA was only weakly detectable in control cells. In contrast, expression of mRNAs encoding the chemokines IL-8, RANTES, or monocyte inflammatory protein-1␣ or -1␤ (MIP-1␣, MIP-1␤) could not be detected (data not shown).
Concomitantly, MCP-1 was liberated into the culture supernatants. Maximal levels of 1365Ϯ215 pg/mL (nϭ3) were observed after 48 hours of stimulation. Secreted MCP-1 was biologically active, and a typical bell-shaped doseresponse curve with a maximal chemotactic index of 3.1 at 10 ng/mL MCP-1 was observed in chemotaxis assays. Specificity was confirmed by a neutralizing anti-MCP-1 antibody, which caused marked reduction of the chemotactic activity. Secretion of IL-8, RANTES, MIP-1␣, and MIP-1␤ remained unaltered.
Induction of gp130 and IL-6 in SMC
Quiescent human vascular SMC expressed scant amounts of gp130 mRNA and no detectable IL-6 receptor (IL-6R) or IL-6 mRNA. Remarkably, E-LDL prominently induced gp130 mRNA. Expression of gp130 was detected after 4 hours of stimulation, peaked at 24 to 48 hours, and vanished thereafter ( Figure 4 ). Basal gp130 expression was undetectable in more than half of the primary SMC cultures analyzed. E-LDL also promoted expression of IL-6 mRNA, which lagged Ϸ4 to 8 hours behind the induction of gp130 mRNA (Figure 3) .
Surface expression of gp130 detected by immunocytochemistry was weak in unstimulated human vascular SMC ( Figure 5 , top) and greatly enhanced after stimulation with 50 g/mL E-LDL for 8 hours (Figure 5, bottom) . Prolonged exposure to E-LDL produced no further enhancement of gp130 surface expression.
Effects of IL-6 and Soluble IL-6R on SMC
In atherosclerotic lesions, SMC are present in the immediate vicinity of infiltrating macrophages. E-LDL induced expression and release of IL-6 from human macrophages and promoted shedding of the soluble IL-6 receptor (sIL-6R). 6 The next experiments were conducted to assess whether IL-6, sIL-6R, or IL-6ϩsIL-6R had an effect on gp130 expression on SMC and whether this effect would be influenced by the additional presence of E-LDL.
Treatment of SMC with IL-6 (250 ng/mL) alone led to an almost imperceptible induction of gp130 mRNA ( Figure 6A) . Similarly, sIL-6R (500 ng/mL) alone provoked only a minor effect ( Figure 6B ). In contrast, simultaneous stimulation with IL-6 (250 ng/mL) and sIL-6R (500 ng/mL) resulted in a sustained, dose-dependent expression of gp130 mRNA (Figure 6C) . The most marked induction of gp130 mRNA was, however, observed when human vascular SMC were preincubated with 50 g/mL E-LDL for 8 hours and then stimulated with the combination of IL-6 and sIL-6R ( Figure 6D ). 
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This resulted in prominent expression of gp130 mRNA after 8 hours, which was maintained for 24 hours.
Toxicity of E-LDL on Human Vascular SMC
Exposure to 200 to 400 g/mL E-LDL reduced the cellular ATP content to Ͻ10% of untreated control SMC after 48 hours (Figure 7) . At E-LDL concentrations Ͻ50 g/mL, cytotoxic effects were observed only after extended incubation (Ͼ48 hours). The cytotoxic effects were not due to apoptosis, as determined by the absence of DNA fragmentations and by negative TUNEL stainings (not shown). The presence of 4% human albumin completely abolished cytotoxicity of E-LDL ( Figure 7 ).
E-LDL Stimulates SMC Proliferation Through 2 Pathways
Albumin was supplemented at 4% to abrogate the cytotoxic effects of E-LDL in the following proliferation assays. E-LDL alone induced moderate dose-dependent proliferation of human vascular SMC, which reached a maximum at 50 g/mL E-LDL ( Figure 8A ). Proliferation commenced after Ϸ24 hours, and a 4-fold increase of DNA synthesis was measured at 72 hours ( Figure 8B ). That the increased incorporation of [ 3 H]-thymidine indeed reflected cell multiplication was ascertained in 4 experiments by direct counting of cells after their release by trypsinization.
An antibody against platelet-derived growth factor (PDGF) reduced the E-LDL-dependent proliferative response by 60%. Blocking fibroblast growth factor (FGF)-␤ activity reduced proliferation by 25%. Combined application of both antibodies was additive and reduced cell proliferation by Ϸ70%. In contrast, antibody against IL-6 was without effect ( Figure 9 ).
As reported above, E-LDL induced release of IL-6 and sIL-6R from macrophages and simultaneously provoked upregulation of gp130 on SMC. It is known that IL-6/sIL-6R can stimulate cells expressing gp130. 18 Therefore, in the next experiments, macrophages were incubated with E-LDL (100 g/mL) for 72 hours, and the supernatants containing 234Ϯ65 pg/mL IL-6 and 987Ϯ122 pg/mL sIL-6R were harvested. E-LDL was removed by centrifugation, and the supernatants were incubated with SMC. When applied to nonactivated SMC, the supernatants only weakly induced cell proliferation ( Figure 10A ). However, if SMC were first preincubated with 25 g/mL E-LDL for 8 hours (to induce gp130), the supernatants provoked a pronounced and sustained proliferative response that was readily apparent after 72 hours ( Figure 10B ). E-LDL alone was without effect.
Discussion
SMC proliferation is a key event in the pathogenesis of atherosclerosis, occurring subsequent to the insudation of LDL, complement activation, and the infiltration of macrophages and T-lymphocytes. Our results show that E-LDL can promote this process through 2 mechanisms. First, E-LDL directly stimulates proliferation, a property that has been described also for other lipoproteins including VLDL and oxidized LDL. 19 -21 We detected no proliferative responses to native LDL, which stands in some disagreement with an earlier study. 20 In the absence of macrophages, E-LDLinduced proliferation appeared to ensue through an autocrine pathway involving PDGF and FGF-␤, as indicated from blocking experiments with antibodies. Arterial SMC express PDGF, 22, 23 and the significance of this growth factor in atherosclerosis is supported by the restricted expression of PDGF receptors on the proliferating SMC subset in the intima, 24 whereas expression is absent on stationary SMC in the media. 25 The rat homologue of human MCP-1 has been linked both to SMC proliferation and migration, 26 and the capacity of E-LDL to stimulate MCP-1 production in both macrophages 6 and SMC is of interest in this context.
The second pathway leading to an SMC-proliferative response integrates the effects of E-LDL on macrophages and on SMC and highlights the central role of IL-6 and sIL-6R. This mechanism is novel and operates through the convergence of 2 events. The first is the release of both IL-6 and its soluble receptor IL-6R from macrophages. The second is the upregulation of gp130, the signal-transducing element of the IL-6 receptor family on SMC provoked by E-LDL.
It is known that IL-6/sIL-6R complexes form spontaneously in solution after their release from cells. The complexes can subsequently bind to and activate cells that express the signal-transducing element gp130. This process, termed transsignaling, is widely operative because gp130 is constitutively expressed on many cell types. 18 SMC are unusual because quiescent SMC express little gp130 but upregulate the molecule when they are stimulated with IL-6/sIL-6R. 13 This drives the cells into a proliferative state. We have found that E-LDL is a second stimulus that causes upregulation of gp130, thus enhancing the efficiency of the transsignaling circuit in SMC. The finding satisfactorily explains why SMC proliferation occurred with a relatively long lag phase and why relatively low concentrations of IL-6/sIL-6R were required. It is of interest that in early atherosclerotic lesions, local expression of IL-6 has indeed been detected particularly in macrophage-rich regions and in SMC. [27] [28] [29] Foam cell formation is another hallmark of the atherosclerotic lesion. Although many studies have analyzed the effects of modified lipoproteins on macrophage foam cell formation, 16, 30 investigations into the pathways underlying cholesterol uptake by SMC have remained sparse. We found that E-LDL induces foam cell transformation of SMC, albeit to a smaller extent than found with macrophages. This was in line with histological studies that identify the majority of foam cells as macrophages, with SMC contributing a smaller fraction. [31] [32] [33] Selective recruitment of monocytes and T-lymphocytes into early atherosclerotic lesions probably reflects lesional expression of selective chemoattractants. 34, 35 Local producers of MCP-1 are mainly macrophages, 34 vascular SMC being additionally involved in the early stages. 36, 37 That E-LDL induced selective production of MCP-1 in SMC is of interest in this context. In accord with immunohistological studies, lower amounts of MCP-1 were liberated by SMC as compared with macrophages. 6 Other lesional components including terminal complement complexes may also contribute to MCP-1 generation in SMC. 38 In vitro, oxidized LDL (ox-LDL) has been shown to be endowed with this capacity, a finding that might attain significance if ox-LDL were present in the lesions in sufficient amounts. 39 The more advanced stages of atherosclerosis are characterized by tissue necrosis. E-LDL induced cytotoxic effects on SMC that were more pronounced than those invoked by ox-LDL. 21 However, in contrast to ox-LDL, 40 E-LDL did not recognizably trigger apoptosis of SMC. This would be in accord with immunohistochemical studies showing apoptosis of macrophages and T-lymphocytes but not of SMC in the lesions. [41] [42] [43] The abolishment of E-LDL toxicity in the presence of 4% human albumin suggested that free fatty acids mediated toxic effects, as has been described for several cell types including lymphocytes, macrophages, and tumor cells. 44, 45 The other biological effects of E-LDL reported here, that is, SMC proliferation and expression of chemokines, were not affected by the addition of albumin.
In sum, our results show that E-LDL is taken up by human vascular SMC and activates these cells to acquire a proinflammatory phenotype. Of particular interest is the finding that the pathways of SMC and macrophage activation by E-LDL may merge at the level of IL-6/s-IL-6R transsignaling, which operates to drive SMC into a proliferative state. The data go further to show that E-LDL is endowed with the prime characteristics of an atherogenic lipoprotein.
